# US 2021/0330649 A1 · Compositions for the prevention and treatment of acute renal injury > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2021/0330649 A1 - Document ID: US20210330649A1 - Status: Published application - Kind: A1 - Application number: 16/624,858 - Filed: 2018-06-20 - Published: 2021-10-28 - Earliest claimed: 2017-06-23 - Assignees: AKI Therapeutics ApS - Applicants: AKI Therapeutics ApS - Inventors: Lars Otto Uttenthal - Web page: https://patentgrep.com/patent/US20210330649A1 ## CPC - A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin - A61P 13/12: of the kidneys - A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)} - A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant - A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60) - A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)} - A61K 31/215: of carboxylic acids - A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} - A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} - A61K 36/258: Panax (ginseng) - A61K 38/13: Cyclosporins - A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof - A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Pharmaceutical compositions are provided for the treatment, pre-emptive treatment or prevention of acute renal injury. ## Claims ### Claim 1 A composition comprising a drug chosen from a cyclosporin, tacrolimus, serolimus or everolimus, wherein said drug is conjugated to a neutrophil gelatinase-associated lipocalin (NGAL) or to a lysozyme or to a low-molecular-weight chitosan, and wherein the conjugate is formulated for intravenous administration to a human subject. ### Claim at position 2 2-14. (canceled) ### Claim 15 (depends on 1) The composition according to claim 1, wherein the drug is cyclosporin A conjugated to recombinantly produced human NGAL, which may optionally lack glycosylation and/or a cysteine residue in position 87 of its protein chain, or to recombinantly produced human lysozyme, or to a low-molecular-weight chitosan. ### Claim 16 (depends on 1) The composition according to claim 1, wherein the drug is cyclosporin G conjugated to recombinantly produced human NGAL, which may optionally lack glycosylation and/or a cysteine residue in position 87 of its protein chain, or to recombinantly produced human lysozyme, or to a low-molecular-weight chitosan. ### Claim 17 (depends on 1) The composition according to claim 1, wherein the drug is oxeclosporin conjugated to recombinantly produced human NGAL, which may optionally lack glycosylation and/or a cysteine residue in position 87 of its protein chain, or to recombinantly produced human lysozyme, or to a low-molecular-weight chitosan. ### Claim 18 (depends on 1) The composition according to claim 1, wherein the drug is chosen from tacrolimus, serolimus or everolimus and said drug is conjugated to recombinantly produced human NGAL, which may optionally lack glycosylation and/or a cysteine residue in position 87 of its protein chain, or to recombinantly produced human lysozyme, or to a low-molecular-weight chitosan. ### Claim 19 (depends on 1) The composition according to claim 1, wherein the NGAL is in the form of any one of NGAL that lacks glycosylation, or NGAL that lacks the cysteine residue in position 87, or NGAL that lacks glycosylation and lacks the cysteine residue in position 87. ### Claim 20 A composition comprising a combination of drugs formulated for intravenous administration to a human subject, the combination of drugs comprising celastrol or pristimerin or betulinic acid in combination with a saponin or flavonoid chosen from diosmin, hesperidin or saponins from Panax quinquefolium. ### Claim 21 (depends on 20) The composition according to claim 20, wherein the combination of drugs comprises betulinic acid and diosmin. ### Claim 22 (depends on 20) The composition according to claim 20, wherein the combination of drugs comprises celastrol and diosmin. ### Claim 23 (depends on 20) The composition according to claim 20, wherein the drugs are conjugated to recombinantly produced human NGAL, which may optionally lack glycosylation and/or a cysteine residue in position 87 of its protein chain, or to a recombinantly produced human lysozyme, or to a low-molecular-weight chitosan, and wherein the conjugate is formulated for intravenous administration to a human subject. ### Claim 24 (depends on 23) The composition according to claim 23, wherein the combination of drugs comprises betulinic acid and diosmin. ### Claim 25 (depends on 23) The composition according to claim 23, wherein the combination of drugs comprises celastrol and diosmin. ### Claim 26 (depends on 1) A method for inhibiting acute renal injury, comprising administering the composition as defined in claim 1 to a subject in need thereof.